Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0013)
Name
Gallic acid
Synonyms
Gallic acid; 3,4,5-Trihydroxybenzoic acid; 149-91-7; gallate; Benzoic acid, 3,4,5-trihydroxy-; Gallic acid, tech.; Kyselina gallova; Pyrogallol-5-carboxylic acid; GALOP; HSDB 2117; CCRIS 5523; 3,4,5-Trihydroxybenzoate; MFCD00002510; NSC 674319; CHEBI:30778; Kyselina 3,4,5-trihydroxybenzoova; AI3-16412; EINECS 205-749-9; NSC 20103; NSC-20103; NSC-674319; UNII-632XD903SP; BRN 2050274; DTXSID0020650; 632XD903SP; NSC20103; DTXCID60650; CHEMBL288114; 3,4,5-trihydroxy-Benzoic acid; 3-10-00-02070 (Beilstein Handbook Reference); NSC674319; NCGC00091125-01; GALLIC ACID ANHYDROUS; Kyselina gallova [Czech]; Acid, Gallic; CAS-149-91-7; Gallic acid [NF]; SR-05000001537; gallic-acid; Kyselina 3,4,5-trihydroxybenzoova [Czech]; Gallic acid tech.; Gallic Acid, F; GDE; Spectrum_000342; 3,4,5-Trihydroxybenzoic acid, anhydrous; SpecPlus_000307; 5-Trihydroxybenzoic acid; Spectrum2_000399; Spectrum3_000254; Spectrum4_001544; Spectrum5_000108; GALLIC ACID [MI]; bmse000389; 3,5-Trihydroxybenzoic acid; GALLIC ACID [HSDB]; GALLIC ACID [INCI]; 3,4,5-hydroxybenzoic acid; WLN: QVR CQ DQ EQ; 3,4,5-trihydroxy-Benzoate; Oprea1_087792; SCHEMBL15012; 3,4,5-Trihydroxybenzoicacid; BSPBio_001668; KBioGR_002008; KBioSS_000822; SPECTRUM210369; BIDD:ER0374; DivK1c_006403; GALLIC ACID [WHO-DD]; SPBio_000617; 3,4,5-Trihydroxybenzoate, X; Benzoic acid,4,5-trihydroxy-; GTPL5549; 3,4,5-Trihydroxybenzoic acid;; KBio1_001347; KBio2_000822; KBio2_003390; KBio2_005958; KBio3_001168; CPD-183; Gallic acid, puriss., 98.0%; HMS1923K07; HMS2091A07; Pharmakon1600-00210369; BCP18127; HY-N0523; NSC36997; Tox21_111089; Tox21_202515; BBL009937; BDBM50085536; CCG-38670; NSC-36997; NSC755825; s4603; STK298718; AKOS000119625; Tox21_111089_1; AC-1206; CS-8191; NSC-755825; PS-8710; SDCCGMLS-0066503.P001; NCGC00091125-02; NCGC00091125-03; NCGC00091125-04; NCGC00091125-05; NCGC00091125-07; NCGC00260064-01; SY038078; SBI-0052184.P002; Gallic acid, 97.5-102.5% (titration); FT-0626592; G0011; EN300-21542; C01424; D85056; 3,4,5-trihydroxybenzoic acid (ACD/Name 4.0); AB00052697_03; Q375837; Q-201146; SR-05000001537-1; SR-05000001537-2; SR-05000001537-3; BRD-K77345217-001-01-9; F1908-0156; Gallic acid, certified reference material, TraceCERT(R); Z104501122; 78563C7D-0E2D-4766-A8EA-670A03C78FCF; GALLIC ACID (CONSTITUENT OF GRAPE SEEDS OLIGOMERIC PROANTHOCYANIDINS); InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; 137657-43-3

    Click to Show/Hide
Status
Investigative
Drug Type
Small molecular drug
Structure
Formula
C7H6O5
IUPAC Name
3,4,5-trihydroxybenzoic acid
Canonical SMILES
C1=C(C=C(C(=C1O)O)O)C(=O)O
InChI
InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)
InChIKey
LNTHITQWFMADLM-UHFFFAOYSA-N
PubChem CID
370
TTD Drug ID
D0Y3TZ
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Cervical cancer ICD-11: 2C77
 Disease Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Necroptosis hsa04217
Cell Process Cell ferroptosis
Cell apoptosis
Cell necroptosis
In Vitro Model HeLa cells Endocervical adenocarcinoma Homo sapiens CVCL_0030
SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
NCI-H446 cells Lung small cell carcinoma Homo sapiens CVCL_1562
Response regulation Gallic acid (GA) could induce coexistence of multiple types of cell death pathways, including apoptosis characterized by mitochondrial cytochromecrelease and caspase-3 activation, ferroptosis characterized by lipid peroxidation, and necroptosis characterized by the loss of plasma membrane integrity in endocervical adenocarcinoma condition.
References
Ref 1 Gallic Acid Triggers Iron-Dependent Cell Death with Apoptotic, Ferroptotic, and Necroptotic Features. Toxins (Basel). 2019 Aug 26;11(9):492. doi: 10.3390/toxins11090492.